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Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Atta 
(EPO) in Acute lschemic Stroke Patients (REGENESIS Trial) 
Steven C Cramer, Univ of California, Irvine, Irvine, CA; Michael D Hill, Univ of Calgary, 
Calgary, Canada; the REGENESIS investigators 
Introduction: Preclinical studies suggest that certain growth factors given in the early days 
after stroke can improve long-term behavioral outcome. An earlier study ("BETAS trial") found 
that 3 doses of b-hCG followed by 3 doses of erythropoietin was safe. The current trial 
(NCT00938314) examined this sequential growth factor study in a Phase Ila, placebo­
controlled, double-blind, randomized trial. Methods: Entry criteria included NIHSS 8-20, 
supratentorial ischemic stroke, 24-48 hr post-stroke at start of therapy; IPA administration was 
an exclusion criterion. Patients received 3 QD doses of SQ b-hCG (10,000 IU) followed by 3 QOD 
doses of IV erythropoietin (EPO). There were 3 equally sized cohorts, each randomized to 
active:placebo in a 3:1 ratio: in Cohort 1, EPO dose=4,000 IU; Cohort 2, 12,000 IU; Cohort 3, 
20,000 IU. Primary outcome measure was change in NIHSS from enrollment to d90. Secondary 
outcome measures included modified Rankin Score (mRS) and Barthel Index at day 90, plus an 
array of exploratory assessments. Due to financial constraints, enrollment was reduced to 96 
patients and moved to India (18 sites). Results: A total of 8 patients died during the trial, the 
distribution of which did not differ by treatment assignment. All but 4 living patients received 
all 6 study doses as planned. Patients were 65 M/21 F, mean (SD) age = 58 (12) yr. At least 
one 15 minute session of post-stroke OT was provided to 25% of patients; PT, to 81 %; and ST, 
to 29%. Median NIHSS at baseline, prior to therapy, was 12.7, decreasing to 7.9 at d30 and 
6.0 at d90. There was no significant difference between active therapy and placebo in any 
endpoint, whether the 3 Cohorts were examined separately or together. Among those patients 
who received OT, both the change in NIHSS and the mRS were significantly better among those 
receiving active therapy as compared to placebo. Discussion: The current trial did not find that 
sequential growth factor therapy inttiated 24-48 hours after stroke onset was associated with 
improved outcome at 90 days based upon the primary outcome measure. The current trial did 
demonstrate that, in the setting of moderate to severe acute ischemic stroke, sequential hCG 
and EPO are safe at the EPO doses examined. Future studies might restrict enrollment to those 
subjects likely to receive physiotherapy. 
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